Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nitric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 10/20 | 0.51 |
| ▸ | CSF1R | P07333 | 8/20 | 0.51 |
| ▸ | KIT | P10721 | 4/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | RAF1 | P04049 | 1/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | LYN | P07948 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1358516 | 0.93 | BRAF (0.56) | BRAFCSF1RKITHDAC3HDAC8 | |
| Nitric Acid SCHEMBL1408807 | 0.91 | BRAF (0.64) | BRAFCSF1RKITLCKSRC | |
| Nitric Acid SCHEMBL1409031 | 0.86 | CSF1R (0.52) | BRAFCSF1RKITLCKSRC | |
| SCHEMBL1409060 | 0.82 | BRAF (0.61) | BRAFCSF1RKITLCKSRC | |
| Nitric Acid SCHEMBL1409086 | 0.81 | PTGS1 (0.50) | BRAFRAF1PDGFRBPDGFRAKDR | |
| Nitric Acid SCHEMBL1448510 | 0.81 | CSF1R (0.47) | BRAFCSF1RKITHDAC6LCK | |
| SCHEMBL1408852 | 0.80 | CSF1R (0.57) | BRAFCSF1RKITLCKSRC | |
| SCHEMBL1358751 | 0.78 | MAPT (0.70) | HDAC3HDAC8HDAC6MAPT | |
| SCHEMBL22024679 | 0.77 | BRAF (0.56) | BRAFCSF1RKITHDAC3HDAC8 | |
| SCHEMBL1358527 | 0.75 | HDAC3 (0.58) | BRAFCSF1RKITHDAC3HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2295424-B1 | Processes for the preparation of novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase | NATCO PHARMA LTD (IN) | 2015-10-14 | — | — | EP | claimed |
| EP-2295424-B1 | Processes for the preparation of novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase | NATCO PHARMA LTD (IN) | 2015-10-14 | — | — | EP | disclosed |
| EP-2265599-B1 | CRYSTAL FORM OF PHENYLAMINOPYRIMIDINE DERIVATIVE | NATCO PHARMA LTD (IN) | 2013-11-20 | — | — | EP | disclosed |
| US-8183253-B2 | Condensing (3-trifluoromethylsulfonyl) benzoyl chloride and 4-methyl-2-nitro-aniline; reducing nitro group with stannous chloride; condensing amino group with cyanamide; cyclocondensing guanidine group with 3-dimethylamino-1-pyridin-3-yl-propenone; antiproliferative agents; chronic myeloid leukemia | NATCO PHARMA LIMITED (IN) | 2012-05-22 | — | — | US | disclosed |
| US-8067422-B2 | Crystal form of phenylamino pyrimidine derivatives | NATCO PHARMA LIMITED (IN) | 2011-11-29 | — | — | US | disclosed |
| US-7910598-B2 | Condensing (3-trifluoromethylsulfonyl) benzoyl chloride and 4-methyl-2-nitro-aniline; reducing nitro group with stannous chloride; condensing amino group with cyanamide; cyclocondensing guanidine group with 3-dimethylamino-1-pyridin-3-yl-propenone; antiproliferative agents | NATCO PHARMA LIMITED (IN) | 2011-03-22 | — | — | US | disclosed |
| EP-2265599-A2 | CRYSTAL FORM OF PHENYLAMINO PYRIMIDINE DERIVATIVE | Natco Pharma Limited (IN) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009109867-A2 | CRYSTAL FORM OF PHENYLAMINO PYRIMIDINE DERIVATIVES | NATCO PHARMA LIMITED (IN) | 2009-09-11 | — | — | WO | disclosed |
| US-20090227611-A1 | CRYSTAL FORM OF PHENYLAMINO PYRIMIDINE DERIVATIVES | NATCO PHARMA LIMITED (IN) | 2009-09-10 | — | — | US | disclosed |
| US-20080306100-A1 | PHENYLAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF BCR-ABL KINASE | NATCO PHARMA LIMITED (IN) | 2008-12-11 | — | — | US | disclosed |
| US-20070232633-A1 | Novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase | NATCO PHARMA LIMITED (IN) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232633-A1 | Novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase | ABL1, ABL2, BCR | BRAF 95/4885CSF1R 524/4885KIT 43/4885 |
| US-20080306100-A1 | PHENYLAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF BCR-ABL KINASE | ABL1, ABL2, BCR | BRAF 35/4885CSF1R 576/4885KIT 189/4885 |
| US-20090227611-A1 | CRYSTAL FORM OF PHENYLAMINO PYRIMIDINE DERIVATIVES | WEE1, TP53, CDKN1A | BRAF 6/4885CSF1R 848/4885KIT 885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.